These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 16544888

  • 21. Validation of an HPLC method for determination of imatinib mesylate in rat serum and its application in a pharmacokinetic study.
    Bende G, Kollipara S, Movva S, Moorthy G, Saha R.
    J Chromatogr Sci; 2010; 48(5):334-41. PubMed ID: 20515524
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
    Haouala A, Zanolari B, Rochat B, Montemurro M, Zaman K, Duchosal MA, Ris HB, Leyvraz S, Widmer N, Decosterd LA.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul 15; 877(22):1982-96. PubMed ID: 19505856
    [Abstract] [Full Text] [Related]

  • 24. Metabolism and disposition of imatinib mesylate in healthy volunteers.
    Gschwind HP, Pfaar U, Waldmeier F, Zollinger M, Sayer C, Zbinden P, Hayes M, Pokorny R, Seiberling M, Ben-Am M, Peng B, Gross G.
    Drug Metab Dispos; 2005 Oct 15; 33(10):1503-12. PubMed ID: 16006570
    [Abstract] [Full Text] [Related]

  • 25. Determination of imatinib plasma levels in patients with chronic myeloid leukemia by high performance liquid chromatography-ultraviolet detection and liquid chromatography-tandem mass spectrometry: methods' comparison.
    Awidi A, Salem II, Najib N, Mefleh R, Tarawneh B.
    Leuk Res; 2010 Jun 15; 34(6):714-7. PubMed ID: 19744707
    [Abstract] [Full Text] [Related]

  • 26. Simultaneous quantitation of azole antifungals, antibiotics, imatinib, and raltegravir in human plasma by two-dimensional high-performance liquid chromatography-tandem mass spectrometry.
    Jourdil JF, Tonini J, Stanke-Labesque F.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Mar 01; 919-920():1-9. PubMed ID: 23384531
    [Abstract] [Full Text] [Related]

  • 27. Simultaneous quantification of erlotinib, gefitinib, and imatinib in human plasma by liquid chromatography tandem mass spectrometry.
    Chahbouni A, den Burger JC, Vos RM, Sinjewel A, Wilhelm AJ.
    Ther Drug Monit; 2009 Dec 01; 31(6):683-7. PubMed ID: 19865001
    [Abstract] [Full Text] [Related]

  • 28. Stability-indicating HPTLC determination of imatinib mesylate in bulk drug and pharmaceutical dosage form.
    Vadera N, Subramanian G, Musmade P.
    J Pharm Biomed Anal; 2007 Jan 17; 43(2):722-6. PubMed ID: 16920319
    [Abstract] [Full Text] [Related]

  • 29. Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection.
    Widmer N, Béguin A, Rochat B, Buclin T, Kovacsovics T, Duchosal MA, Leyvraz S, Rosselet A, Biollaz J, Decosterd LA.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Apr 25; 803(2):285-92. PubMed ID: 15063337
    [Abstract] [Full Text] [Related]

  • 30. Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography-triple-quadrupole and linear ion trap mass spectrometers.
    Marull M, Rochat B.
    J Mass Spectrom; 2006 Mar 25; 41(3):390-404. PubMed ID: 16470567
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting.
    Faber E, Friedecký D, Mičová K, Rožmanová S, Divoká M, Jarošová M, Indrák K, Adam T.
    Ann Hematol; 2012 Jun 25; 91(6):923-9. PubMed ID: 22231281
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies.
    Hernández-Boluda JC, Cervantes F.
    Drugs Today (Barc); 2002 Sep 25; 38(9):601-13. PubMed ID: 12582448
    [Abstract] [Full Text] [Related]

  • 35. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study.
    Pappas P, Karavasilis V, Briasoulis E, Pavlidis N, Marselos M.
    Cancer Chemother Pharmacol; 2005 Oct 25; 56(4):358-60. PubMed ID: 15883819
    [Abstract] [Full Text] [Related]

  • 36. A validated LC method for imatinib mesylate.
    Vivekanand VV, Sreenivas Rao D, Vaidyanathan G, Sekhar NM, Avijit Kelkar S, Ramachandra Puranik P.
    J Pharm Biomed Anal; 2003 Dec 04; 33(5):879-89. PubMed ID: 14656579
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations.
    Schleyer E, Pursche S, Köhne CH, Schuler U, Renner U, Gschaidmeier H, Freiberg-Richter J, Leopold T, Jenke A, Bonin M, Bergemann T, le Coutre P, Gruner M, Bornhäuser M, Ottmann OG, Ehninger G.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Jan 05; 799(1):23-36. PubMed ID: 14659433
    [Abstract] [Full Text] [Related]

  • 40. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice.
    Zhou L, Schmidt K, Nelson FR, Zelesky V, Troutman MD, Feng B.
    Drug Metab Dispos; 2009 May 05; 37(5):946-55. PubMed ID: 19225039
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.